Are you Dr. Schranz?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 8 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
51 Goldfinch Circle
Phoenixville, PA 19460Phone+1 610-585-6294- Is this information wrong?
Summary
- Dr. Jennifer Schranz, MD is an infectious disease specialist in Phoenixville, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
Stony Brook Medicine/University HospitalFellowship, Infectious Disease, 1993 - 1995
University of Toronto Faculty of MedicineClass of 1989
Certifications & Licensure
PA State Medical License 1998 - 2024
Publications & Presentations
PubMed
- 44 citationsPharmacokinetics of Solithromycin (CEM-101) after Single or Multiple Oral Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult SubjectsJ. Gordon Still, Jennifer Schranz, Thorsten P. Degenhardt, Drusilla Scott, Prabhavathi Fernandes, Maria J. Gutierrez, Kay Clark> ;Antimicrobial Agents and Chemotherapy. 2011 May 1
- 27 citationsA phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis.Jose A. Vazquez, Jennifer Schranz, Kay Clark, Beth P. Goldstein, Annette C. Reboli, Carl J. Fichtenbaum> ;Journal of Acquired Immune Deficiency Syndromes. 2008 Jul 1
- 590 citationsAnidulafungin versus Fluconazole for Invasive CandidiasisAnnette C. Reboli, Coleman Rotstein, Peter G. Pappas, Stanley W. Chapman, Daniel H. Kett, Deepali Kumar, Robert F. Betts, Michele Wible, Beth P. Goldstein, Jennifer Sc...> ;The New England Journal of Medicine. 2007 Jun 14
- Join now to see all
Press Mentions
Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (Lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)October 15th, 2019- Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults with Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical TrialSeptember 27th, 2019
Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical AssociationSeptember 27th, 2019- Join now to see all
